Clinical Trials Logo

Liver Transplantation clinical trials

View clinical trials related to Liver Transplantation.

Filter by:

NCT ID: NCT00722332 Completed - Hepatitis B Clinical Trials

Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients

Start date: February 2008
Phase: Phase 4
Study type: Interventional

The purpose of the study is to assess the pharmacokinetics, safety and efficacy of HepaGam B in combination with antiviral therapy for the prevention of hepatitis B virus (HBV) recurrence following HBV-related orthotopic liver transplant.

NCT ID: NCT00720408 Completed - Clinical trials for Liver Transplantation

A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Liver Transplant Recipients.

Start date: December 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of Prograf extended release(XL) plus MMF with Prograf plus MMF and steroid withdrawal in de novo Liver transplant recipients

NCT ID: NCT00719745 Completed - Clinical trials for Liver Transplantation

A Study to Assess the Safety and Efficacy of Prograf and MR4 in Liver Transplant Recipients

Start date: February 2006
Phase: Phase 3
Study type: Interventional

To evaluate and to compare efficacy and safety of MR4 versus Prograf in patients undergoing primary liver transplantation.

NCT ID: NCT00717314 Completed - Clinical trials for Liver Transplantation

A Study of CellCept (Mycophenolate Mofetil) Combined With Calcineurin Inhibitors in Liver Transplant Patients.

Start date: May 2008
Phase: Phase 4
Study type: Interventional

This 2 arm study will compare the efficacy and safety of switching to CellCept combined with different regimens of reduced calcineurin inhibitors (CNI) in patients with liver transplants. Patients currently receiving CNI treatment will be randomized into one of 2 groups to receive either 1) CellCept 2.0g/day po bid + 50% reduction of CNI from baseline or 2) CellCept 2.0g/day po bid + >=75% reduction of CNI from baseline. The anticipated time on study treatment is 1 year, and the target sample size is <100 individuals.

NCT ID: NCT00698399 Completed - Liver Transplant Clinical Trials

Serum Markers of Ischemia Reperfusion Injury in Liver Transplant Patients

Start date: March 2008
Phase: N/A
Study type: Observational

This is an observational study examining serum markers in patients who are undergoing either a cadaveric liver transplant or a living related liver transplant.

NCT ID: NCT00693524 Completed - Clinical trials for Liver Transplantation

Sequential Therapy (FK506 + Monoclonal Anti-IL2R Antibodies + MMF) Versus FK506 With Steroids in Liver TX

TAST
Start date: November 2002
Phase: Phase 2
Study type: Interventional

Study to evaluate the benefits and any risks of the delayed administration of tacrolimus in a combined regimen of mycophenolate mofetil and monoclonal anti-IL2R antibodies (daclizumab), in comparison with a standard steroid + tacrolimus double drug regimen

NCT ID: NCT00682110 Completed - Clinical trials for Liver Transplantation

Hemodynamic Measurements During Liver Transplantation

OLT
Start date: July 2007
Phase: N/A
Study type: Observational

The purpose of the study is to determine if the less invasive monitors are as reliable for measuring heart function in patients undergoing liver transplantation as the more invasive pulmonary artery.

NCT ID: NCT00677625 Completed - Liver Disease Clinical Trials

Pediatric Liver Database

Start date: June 2003
Phase: N/A
Study type: Observational

The purpose of this study is to collect data to examine and characterize the clinical outcomes of pediatric patients diagnosed with any liver disease at Children's Hospital of Wisconsin.

NCT ID: NCT00668369 Completed - Clinical trials for Liver Transplantation

Effect of Immunosuppression Drug Weaning on Hepatitis C Virus (HCV)-Induced Liver Damage After Liver Transplantation

Start date: April 2008
Phase: Phase 2
Study type: Interventional

Viral infections can profoundly influence alloimmune responses and hamper allograft tolerance induction. Persistent hepatitis C virus (HCV) infection occurs in 50% of liver and 20% of kidney transplant recipients, but the impact of HCV on the acquisition of allograft tolerance has not been elucidated. Liver transplantation constitutes a unique clinical model to address this question, given that up to 20% of liver recipients can completely discontinue immunosuppressive drugs and attain operational tolerance. The goal of our study is to determine the influence of HCV-driven immune responses on the acquisition of operational tolerance in liver transplant recipients following drug weaning, and to assess whether immunosuppression withdrawal ameliorates HCV-induced liver damage. This is a prospective trial in which immunosuppressive drug weaning will be offered to HCV-positive liver recipients (selected on the basis of a high likelihood of tolerance) as a strategy to improve HCV-mediated liver disease.

NCT ID: NCT00622869 Completed - Clinical trials for Liver Transplantation

Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients

RAD
Start date: January 2008
Phase: Phase 3
Study type: Interventional

This trial was designed to address important issues that impact recipients of liver allografts as well as clinicians, ie, renal function, reduction or discontinuation of tacrolimus early post-transplantation, and progression rate of fibrosis in hepatitis C virus (HCV) positive patients.